Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Weekly Wrap 18 March

Sophia Mavridis
March 18, 2022

Morning Bell 17 March

Paulina Peters
March 17, 2022

Morning Bell 16 March

Sophia Mavridis
March 16, 2022

Morning Bell 15 March

Paulina Peters
March 15, 2022

Morning Bell 14 March

Sophia Mavridis
March 14, 2022

Weekly Wrap 11 March

Sophia Mavridis
March 11, 2022

Morning Bell 10 March

Sophia Mavridis
March 10, 2022

Morning Bell 9 March

Paulina Peters
March 9, 2022

Morning Bell 8 March

Sophia Mavridis
March 8, 2022

Morning Bell 7 March

Sophia Mavridis
March 7, 2022

Weekly Wrap 4 March

Sophia Mavridis
March 4, 2022

Morning Bell 3 March

Sophia Mavridis
March 3, 2022